Company intelligence / Profile preview

LumaMed

Ownership: Private
Development stage: Preclinical

Overview

LumaMed has developed the LumaScan device, a tabletop inverted microscope designed to help surgeons visualize tumor margins during excision procedures. The technology aims to reduce repeat surgeries by providing real-time margin assessment. It has received grants from the National Cancer Institute and private investment but was not yet commercially available as of the last update. Clinical results are focused on improving surgical outcomes in breast and other solid tumor surgeries by enhancing intraoperative decision-making regarding tissue margins.

Therapeutic areas: Oncology
Modalities: DeviceDigital health tool
Industry: Pathology

Partnerships

University of Massachusetts Medical School

Beyond the preview

Go deeper on LumaMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LumaMed.

Explore the full profile